TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)

19.5
+0.28  (+1%)
Previous Close 19.22
Open 19.48
Price To Book 1.38
Market Cap 60,752,858,244
Shares 3,115,531,192
Volume 785,123
Short Ratio 1.87
Av. Daily Volume 1,367,429
Stock charts supplied by TradingView

NewsSee all news

  1. Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML

    – Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) Annual Meetings – – Findings Support Response-Based Dosing

  2. Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

    Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation is designed to enhance the treatment administration experience for HAE patients

  3. Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS

    – Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS, With Safety Profile Similar to Azacitidine Alone – – Pevonedistat Could be First New Treatment Option

  4. European Commission Releases Takeda From Commitment to Divest Shire's Pipeline Compound SHP647

    Takeda Pharmaceutical Company Limited ((

  5. Racing against time, medical researchers, life science companies and COVID-19 survivors launch national campaign to drive blood plasma donation

     A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups has come together to support the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met PFS and OS endpoints - April 20, 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 interim analysis due 2H 2020.
Cabozantinib - COSMIC-311
Thyroid Carcinoma
Phase 2 top-line data due 4Q 2020.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 3 PFS and interim OS analysis due 2H 2020.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 3 data due 2022.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Phase 4 PFS data due 2020.
Cabozantinib
Medullary Thyroid Cancer
Phase 2 trial has completed enrolment.
Mobocertinib (TAK-788) - EXCLAIM
non-small cell lung cancer (NSCLC)
Phase 3 trial is enrolling.
Mobocertinib EXCLAIM-2
NSCLC with EGFR exon 20 insertion mutations
Phase 1/2 trial has completed enrolment.
Mobocertinib (TAK-788)
Non-Small Cell Lung Cancer
FDA Approval announced May 22, 2020.
ALUNBRIG (brigatinib)
ALK+ Metastatic Non-Small Cell Lung Cancer
Phase 3 trial is enrolling.
ALUNBRIG versus alectinib ALTA 3
ALK+ Advanced NSCLC
Phase 3 trial did not meet primary endpoint - March 10, 2020.
NINLARO (ixazomib) lenalidomide and dexamethasone - TOURMALINE-MM2
Multiple myeloma
Initiation of development announced March 4, 2020.
Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)
COVID-19
CRL issued December 21, 2020.
Entyvio
Ulcerative Colitis
Phase 3 trial met primary endpoint - July 22, 2020.
Vedolizumab
Crohn's Disease
Phase 3 trial met primary endpoint - November 8, 2019.
Ixazomib - TOURMALINE-MM4
Multiple myeloma
Phase 2 data to be presented at EHA June 11-14, 2020.
Ponatinib (OPTIC) (EHA)
Chronic Myeloid Leukemia

Latest News

  1. Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML

    – Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) Annual Meetings – – Findings Support Response-Based Dosing

  2. Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

    Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation is designed to enhance the treatment administration experience for HAE patients

  3. Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS

    – Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS, With Safety Profile Similar to Azacitidine Alone – – Pevonedistat Could be First New Treatment Option

  4. European Commission Releases Takeda From Commitment to Divest Shire's Pipeline Compound SHP647

    Takeda Pharmaceutical Company Limited ((

  5. Racing against time, medical researchers, life science companies and COVID-19 survivors launch national campaign to drive blood plasma donation

     A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups has come together to support the

  6. Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

    REDMOND, Wash. and NEW YORK, May 26, 2020 /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and

  7. U.S. FDA Approves Takeda's ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

    − Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases Takeda

  8. Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline

    – Scientific Advancements Seek to Address Therapeutic Needs in Underserved Oncology Communities, Including Rare Leukemias and NSCLCs – New Clinical Data Offer Practice-Changing Potential in Treatment of Chronic

  9. European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

    – Approval is Based on Results of Phase 3 ECHELON-2 Trial, Which Demonstrated Treatment with ADCETRIS Plus CHP (cyclophosphamide, doxorubicin, prednisone) Resulted in Significant Improvement in Progression-Free Survival

  10. Takeda Accelerates Transformation: Solid FY2019 Results, Confidence in FY2020 Growth Momentum

    Takeda Pharmaceutical Company Limited (TYO:4502) (NYSE:TAK) ("Takeda") today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical company, Takeda is

  11. European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

    − Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn's disease − Additional

  12. CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

    OSAKA, Japan, and KING OF PRUSSIA, Pa., May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived

  13. NYSE Board Advisory Council Welcomes Eight New Members

    Council connects diverse board candidates with NYSE-listed companies seeking new directors The New York Stock Exchange (NYSE), a wholly-owned subsidiary of Intercontinental Exchange (NYSE:ICE), welcomed eight new